@article{ae133a8387ba40d796a0456cbbd7318b,
title = "Why the Low-Pressure Glaucoma Treatment Study makes sense",
keywords = "brimonidine, disc hemorrhage, nitric oxide, retinal vascular autoregulation, the Low-Pressure Glaucoma Treatment Study",
author = "Pasquale, {Louis R.} and Gilbert Feke and Alon Harris",
note = "Funding Information: L Pasquale has received research funding from Allergan, Inc. on healthcare economics research, but no pharmaceutical company sponsored the investigator-initiated efforts discussed here. A Harris is a consultant to Merck, Allergan, Alcon, Pharmalight and Sucampo but no funds were provided in support of this editorial. The Glaucoma Service at Massachusetts Eye and Ear Infirmary is a recipient of a Horizon Grant from Allergan, Inc., but this support was not used in any of the publications by the authors quoted here. Some of the work quoted here is supported by NEI grant RO1 EY015473 (PI: L Pasquale). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",
year = "2012",
month = aug,
doi = "10.1586/eop.12.36",
language = "English",
volume = "7",
pages = "295--297",
journal = "Expert Review of Ophthalmology",
issn = "1746-9899",
publisher = "Taylor and Francis Ltd.",
number = "4",
}